Latest Ltr Pharma (ASX:LTP) News

LTR Pharma has announced that its erectile dysfunction treatment SPONTAN now boasts an 18-month shelf life, surpassing commercial standards and paving the way for international market growth.

LTR Pharma’s intranasal ED treatment SPONTAN achieves peak effect up to five times faster than oral tablets, according to new peer-reviewed clinical data published in a leading European journal.

LTR Pharma has initiated commercial distribution of its nasal spray SPONTAN through Australia's Symbion pharmacy network and is advancing ROXUS development for a US launch in early 2026, while expanding its pipeline with a new intranasal treatment for swallowing disorders.

LTR Pharma has successfully completed the extractables study for its intranasal erectile dysfunction spray SPONTAN, confirming safety compliance and initiating the next phase of leachables testing to support FDA approval.

LTR Pharma has appointed Associate Professor Darren Katz, a leading urologist and erectile dysfunction expert, to its Scientific Advisory Board, aiming to fast-track the development and commercialization of its innovative nasal spray treatments SPONTAN and ROXUS.

LTR Pharma has expanded patient access to its fast-acting erectile dysfunction treatment SPONTAN by partnering with TerryWhite Chemmart’s extensive pharmacy network, marking a significant step in its commercial rollout and regulatory strategy.

LTR Pharma has partnered with Strategic Drug Solutions to co-develop OROFLOW®, a novel intranasal spray aimed at providing fast symptom relief for Oesophageal Motility Disorders, tapping into a growing $4.5 billion global market.

LTR Pharma reports strong Q1 2025 progress with FDA pre-IND meeting success, scientific acclaim for SPONTAN’s rapid absorption, and strategic launch of ROXUS to fast-track US market entry.

LTR Pharma reports compelling clinical results for its nasal spray ED treatment SPONTAN®, demonstrating rapid absorption and strong safety, alongside strategic partnerships and a robust $34 million cash position.

LTR Pharma has inked a national distribution agreement with Symbion, positioning its innovative ED treatment SPONTAN® for broad pharmacy access across Australia ahead of its commercial launch.